Collaboration versus outsourcing: The need to think outside the box

Future Medicinal Chemistry

Volumn 3, Issue 16, 2011, Pages 1995-2020

  Robertson, Graeme M ^a   Mayr, Lorenz M ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NEW DRUG;

ALZHEIMER DISEASE; BIOTECHNOLOGY; CLINICAL STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; CULTURAL FACTOR; DECISION MAKING; DISEASE COURSE; DRUG INDUSTRY; FINANCIAL MANAGEMENT; HUMAN; KNOWLEDGE; MEDICAL SOCIETY; ONCOLOGY; PARKINSON DISEASE; PREDICTION; PRIORITY JOURNAL; PRODUCTIVITY; PUBLIC-PRIVATE PARTNERSHIP; RELIABILITY; RESEARCH; REVIEW; STANDARDIZATION;

COOPERATIVE BEHAVIOR; DRUG DISCOVERY; OUTSOURCED SERVICES;

EID: 81855183788     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.11.160     Document Type: Review

References (120)

1. Garnier J-P. Rebuilding the R&D engine in big pharma. Harvard Bus. Rev. 86(5), 68-76, (2008).
2. Miller G. Is pharma running out of brainy ideas? Science 329(5991), 502-504 (2010).
3. Littman BH, Marincola FM. Create a translational medicine knowledge repository - research downsizing, mergers and increased outsourcing have reduced the depth of in-house translational medicine expertise and institutional memory at many pharmaceutical and biotech companies: How will they avoid relearning old lessons? J. Transl. Med. 9, 56 (2011).
4. Lundberg JM, Reilly C. The road ahead for large pharma: long-term science and innovation. Drug Discov. Today 14(9-10), 439-441 (2009).
5. Cressey D. Traditional drug discovery model ripe for reform. Nature 471(7336), 17-18 (2011).
6. PriceWaterhouseCoopers. Pharma 2020: Challenging Business Models. Which Path Will You Take? PriceWaterhouseCoopers, London, UK (2009).
7. Bloch M, Dhankhar A, Narayanan S. Pharma leaps offshore. McKinsey Quarterly. July (2006).
8. Baxendale IR, Hayward JJ, Ley SV et al. Pharmaceutical strategy and innovation: an academics perspective. ChemMedChem 2(6), 768-788 (2007).
9. Bennani YL. Drug discovery in the next decade innovation needed ASAP. Drug Discov. Today 16(17-18), 779-792(2011).
10. Hoffmann T, Bishop C. The future of discovery chemistry: quo vadis? Academic to industrial-the maturation of medicinal chemistry to chemical biology. Drug Discov. Today 15(7-8), 260-264 (2010).
11. Frye S, Crosby M, Edwards T, Juliano R. US academic drug discovery. Nat. Rev. Drug Discov. 10(6), 409-410 (2011).
12. David E, Mehta A, Norris T et al. New frontiers in pharma R&D investment. McKinsey Quarterly. February (2010).
13. Whitty A. Growing PAINS in academic drug discovery. Future Med. Chem. 3(7), 797-801 (2011).
14. Kotz J. Small (molecule) thinking in academia. SciBX 4, 1-4 (2011).
15. Stevens AJ, Jensen JJ, Wyller K et al. The role of public-sector research in the discovery of drugs and vaccines. N. Engl. J. Med. 364(6), 535-541 (2011).
16. Trojanowski JQ, Arnold SE, Karlawish JH et al. Design of comprehensive Alzheimer's disease centers to address unmet national needs. Alzheimers Dement. 6(2), 150-155 (2010).
17. Everts M, Knight WB, Harris DR et al. The Alabama Drug Discovery Alliance: a collaborative partnership to facilitate academic drug discovery. Pharm. Res. 28(7), 1454-1459 (2011).
18. Pisano GP. Can science be a business? Lessons from biotech. Harv. Bus. Rev. 84(10), 114-124, 150 (2006).
19. Jones A. Minimizing leakage of value from R&D alliances. Nat. Rev. Drug. Discov. 6(9), 711-719 (2007).
20. Müller S, Weigelt J. Open-access public- private partnerships to enable drug discovery - new approaches. IDrugs. 13(3), 175-180 (2010).
21. Edwards A. Open-source science to enable drug discovery. Drug Discov. Today 13(17-18), 731-733 (2008).
22. PriceWaterhouseCoopers. Pharma 2020: Virtual R&D. Which Path Will You Take? PriceWaterhouseCoopers, London, UK (2008).
23. Robertson G. Chemistry at the Biology Interface. MedChemWatch (12) 50-54 (2011).
24. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8(12), 959-968 (2009).
25. O'Dell C, Grayson CJ. If Only We Knew What We Know: The Transfer of Internal Knowledge and Best Practice. The Free Press, NY, USA (1998).
26. Munos BH, Chin WW. A call for sharing adapting pharmaceutical research to new realities. Sci. Transl. Med. 1(9), 9cm8 (2009).
27. Arrowsmith J. Trial watch: Phase II failures: 2008-2010. Nat. Rev. Drug Discov. 10(5), 328-329 (2011).
28. Arrowsmith J. Trial watch: Phase III and submission failures: 2007-2010. Nat. Rev. Drug Discov. 10(2), 87 (2011).
29. Woodcock J. Precompetitive research: a new prescription for drug development? Clin. Pharmacol. Ther. 87(5), 521-523 (2010).
30. Lee JA, Chu S, Willard FS et al. Open innovation for phenotypic drug discovery: the PD2 assay panel. J. Biomol. Screen. 16(6), 588-602 (2011).
31. Fox D. Sharing our collective wisdom to design better medicines. MedChemWatch (11), 24-27 (2010).
32. Goldman M. Reflections on the Innovative Medicines Initiative. Nat. Rev. Drug Discov. 10(5), 321-322 (2011).
33. Kamel N, Compton C, Middelveld R et al. The Innovative Medicines Initiative (IMI): a new opportunity for scientific collaboration between academia and industry at the European level. Eur. Respir. J. 31(5), 924-926 (2008).
34. Clark DE. Outsourcing lead optimization: the eye of the storm. Drug Discov. Today 16(3-4), 147-157 (2011).
35. Festel G. Outsourcing chemical synthesis in the drug discovery process. Drug Discov. Today 16(5-6), 237-243 (2011).
36. Meerpoel L, Schroven M, Goris K et al. Outsourcing to exploit a key asset. Drug Discov. Today 11(11-12), 556-560 (2006).
37. Brower V. Going global in R&D. EMBO Rep. 5(4), 333-335 (2004).
38. Patlak M. Competitors try collaboration to speed drug development. J. Natl Cancer Inst. 102(12), 841-843 (2010).
39. Norman T, Edwards A, Bountra C et al. The precompetitive space: time to move the yardsticks. Sci. Transl. Med. 3(76), 76cm10 (2011).
40. Chakma J, Calcagno JL, Behbahani A et al. Is it virtuous to be virtual? The VC viewpoint. Nat. Biotechnol. 27(10), 886-888 (2009).
41. Hanauer SB. Outsourcing clinical trials. Nat. Rev. Gastroenterol. Hepatol. 6(4), 191 (2009).
42. Drabu S, Gupta A, Bhadauria A. Emerging trends in contract research industry in India. Contemp. Clin. Trials 31(5), 419-422 (2010).
43. Roberson TA, Smith NV, Scherer J. Transforming drug discovery with a fully outsourced model. Pharma. Outsourc. 18-22 (2009).
44. Longman R. Lilly's chorus experiment. In vivo: The Business & Medicine Report. 25, 1-5 (2007).
45. Vallance P, Williams P, Dollery C. The future is much closer collaboration between the pharmaceutical industry and academic medical centers. Clin. Pharmacol. Ther. 87(5), 525-527 (2010).
46. Knowles RG. Challenges for the development of new treatments for severe asthma: a pharmaceutical perspective. Curr. Pharm. Des. 17(7), 699-702 (2011).
47. Ismail A. Outsourcing in silico predictive toxicology: technologies, markets and paradigms. Future Med. Chem. 2(10), 1507-1510 (2010).
48. Cyranoski D. Pharmaceutical futures: made in China? Nature 455(7217), 1168-1170 (2008).
49. Silber BM. Driving drug discovery: the fundamental role of academic labs. Sci. Transl. Med. 2(30), 30cm16 (2010).
50. Hruby VJ. Organic chemistry and biology: chemical biology through the eyes of collaboration. J. Org Chem. 74(24), 9245-9264 (2009).
51. West W, Nightingale P. Organizing for innovation: towards successful translational research. Trends Biotechnol. 27(10), 558-561 (2009).
52. Gardell SJ, Roth GP, Kelly DP. Cardiovascular drug discovery in the academic setting building infrastructure, harnessing strengths, and seeking synergies. J. Cardiovasc. Transl. Res. 3(5), 431-437 (2010).
53. Erickson J. Translation research and drug development. Science 312(5776), 997b (2006).
54. Altshuler JS, Balogh E, Barker AD et al. Opening up to precompetitive collaboration. Sci. Transl. Med. 2(52), 52cm26 (2010).
55. Allerheiligen SRB. Next-generation model-based drug discovery and development: quantitative and systems pharmacology. Clin. Pharmacol. Ther. 88(1), 135-137 (2010).
56. Druker BJ. Perspectives on the development of imatinib and the future of cancer research. Nat. Med. 15(10), 1149-1152 (2009).
57. Gilardoni F, Arvanites AC. Virtual drug discovery: beyond computational chemistry? Expert Opin. Drug Discov. 5(2), 113-115 (2010).
58. Allarakhia M. Developing a framework for understanding and enabling open source drug discovery. Expert Opin. Drug Discov. 5, 1-6 (2010).
59. Frearson J, Wyatt P. Drug discovery in academia - the third way? Expert Opin. Drug Discov. 5(10), 909-919 (2010).
60. Hughes B. A Wellcome experiment in seeding drug discovery. Nat. Rev. Drug Disc. 9(3), 178-180 (2010).
61. Lessl M. Grants4Targets - an innovative approach to translate ideas from basic research into novel drugs. Drug Discov. Today 16(7-8), 288-292(2011).
62. Lessl M, Bryans JS, Richards D et al. Crowd sourcing in drug discovery. Nat. Rev. Drug Discov. 10(4), 241-242 (2011).
63. Munoz-Sanjuan I, Bates GP. The importance of integrating basic and clinical research toward the development of new therapies for Huntington's disease. J. Clin. Invest. 121(2), 476-483 (2011).
64. Chatelain E, Ioset JR. Drug discovery and development for neglected diseases the DNDi model. Drug Des. Devel. Ther. 5, 175-181 (2011).
65. Nwaka S, Ramirez B, Brun R et al. Advancing drug innovation for neglected diseases - criteria for lead progression. PLoS Negl. Trop. Dis. 3(8), e440 (2009).
66. Webb S. Public-private partnership tackles TB challenges in parallel. Nat. Rev. Drug. Discov. 8(8), 599-600 (2009).
67. Matter A, Keller TH. Impact of non-profit organizations on drug discovery: opportunities, gaps, solutions. Drug Discov. Today 13(7-8), 347-352 (2008).
68. Kar S. Open innovation: an answer for neglected diseases. Future Med. Chem. 2(9), 1411-1415 (2010).
69. Lexchin J. One step forward, one step sideways? Expanding research capacity for neglected diseases. BMC Int. Health Hum. Rights. 10, 20-30 (2010).
70. Hunter J. Challenges for pharmaceutical industry: new partnerships for sustainable human health. Philos. Transact. A Math. Phys. Eng. Sci. 369(1942), 1817-1825 (2011).
71. Billington C, Davidson R. Using knowledge brokering to improve business processes. McKinsey Quarterly. January (2010).
72. Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6(11), 881-890 (2007).
73. Hunter J, Stephens S. Is open innovation the way forward for big pharma? Nat. Rev. Drug Discov. 9(2), 87-88 (2010).
74. Brown FK, Maliski E, Waller C. Data is the currency of R&D, and that currency is now generated and traded globally. Curr. Opin. Drug Discov. Devel. 13(3), 275-278 (2010).
75. Abad-Zapatero C. A sorcerer's apprentice and the rule of five: from rule-of-thumb to commandment and beyond. Drug Discov. Today 12(23-24), 995-997 (2007).
76. Houlton S. Wellcome boost for open-access chemistry. Nat. Rev. Drug Discov. 7(10),789-790 (2008).
77. Friend SH. The need for precompetitive integrative bionetwork disease model building. Clin. Pharmacol. Ther. 87(5), 536-539 (2010).
78. Chesler EJ. Baker EJ. The importance of open-source integrative genomics to drug discovery. Curr. Opin. Drug Discov. Dev. 13(3), 310-316 (2010).
79. Hughes B. Harnessing open innovation. Nat. Rev. Drug Discov. 8(5), 344-345 (2009).
80. Samwald M, Jentzsch A, Bouton C et al. Linked open drug data for pharmaceutical research and development. J. Cheminform. 3(1), 19-24 (2011).
81. Wagner JA, Prince M, Wright EC et al. The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration. Clin. Pharmacol. Ther. 87(5), 539-542 (2010).
82. Zerhouni EA, Sanders CA, von Eschenbach AC. The Biomarkers Consortium: public and private sectors working in partnership to improve public health. Oncologist 12(3), 250-252 (2007).
83. Eck SL, Paul SM. Biomarker qualification via public-private partnerships. Clin. Pharmacol. Ther. 87(1), 21-23 (2010).
84. Zerhouni EA, Potocnik J. European Union and NIH collaborate. Science 322(5904), 1048 (2008).
85. Roy A, McDonald PR, Sittampalam S et al. Open access high throughput drug discovery in the public domain: a Mount Everest in the making. Curr. Pharm. Biotechnol. 11(7), 764-778 (2010).
86. Coons SJ. The FDA's critical path initiative a brief introduction. Clin. Ther. 31(11), 2572-2573 (2009).
87. Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu. Rev. Med. 59, 1-12 (2008).
88. Woosley RL, Myers RT, Goodsaid F. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science. Clin. Pharmacol. Ther. 87(5), 530-533 (2010).
89. Romero K, de Mars M, Frank D et al. The Coalition Against Major Diseases - developing tools for integrated drug development process in Alzheimer's and Parkinson's diseases. Clin. Pharmacol. Ther. 86(4), 365-367 (2009).
90. Hunter AJ. The Innovative Medicines Initiative: a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients. Drug Discov. Today 13(9-10), 371-373 (2008).
91. Brady LS, Winsky L, Goodman W et al. NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing. Neuropsychopharmacology 34(1), 229-243 (2009).
92. Finkbeiner S. Bridging the valley of death of therapeutics for neurodegeneration. Nat. Med. 16(11), 1227-1232 (2010).
93. Rai AK, Reichman JH, Uhlir PF et al. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery. Yale J. Health Policy Law Ethics 8(1), 1-36 (2008).
94. Butler D. Crossing the valley of death. Nature 453(7197), 840-842 (2008).
95. Schreiber S. Organic synthesis toward small-molecule probes and drugs. Proc. Natl Acad. Sci. USA 108(17), 6699-6702 (2011).
96. Melese T, Lin SM, Chang JL et al. Open innovation networks between academia and industry: an imperative for breakthrough therapies. Nat. Med. 15(5), 502-507 (2009).
97. Munos B. Can open-source drug R&D repower pharmaceutical innovation? Clin. Pharmacol. Ther. 87(5), 534-536 (2010).
98. Weigelt, J. The case for open-access chemical biology. A strategy for pre-competitive medicinal chemistry to promote drug discovery. EMBO Rep. 10(9), 941-945 (2009).
99. Barnes, MR Harland L, Foord SM et al. Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery. Nat. Rev. Drug Discov. 8(9), 701-708 (2009).
100. McCarthy A. The Broad Institute - six years later. Chem. Biol. 17(4), 311-312 (2010).
101. Wagner JA. Open-minded to open innovation and precompetitive collaboration. Clin. Pharmacol. Ther. 87(5), 511-515 (2010).
102. Vargas G, Boutouyrie B, Ostrowitzki S et al. Arguments against precompetitive collaboration. Clin. Pharmacol. Ther. 87(5), 527-529 (2010).
103. Norman TC, Bountra C, Edwards AM et al. Leveraging crowdsourcing to facilitate the discovery of new medicines. Sci. Transl. Med. 3(88), 88mr1 (2011).
104. Kozikowski AP, Roth B, Tropsha A. Why academic drug discovery makes sense. Science 313(5791), 1235-1238 (2006).
105. Kleyn, D, Kitney R, Atun RA. Partnership and innovation in the life sciences. Int. J. Innovation Manag. 11, 323-347 (2007).
106. Waldman SA, Terzic A. Molecular therapeutics from knowledge to delivery. Clin. Pharm. Ther. 87(6), 619-623 (2010).
107. Crommelin D, Stolk P, Besançon L et al. Pharmaceutical sciences in 2020. Nat. Rev. Drug Discov. 9(2), 99-100 (2010).
108. Paul SM, Mytelka DS, Dunwiddie CT et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat.Rev. Drug Discov. 9(3), 203-214 (2010).
109. Castoreno AB, Eggert US. Small-molecule probes of cellular pathways and networks. ACS Chem. Biol. 6(1), 86-94 (2011).
110. Gray NS. Drug discovery through industry-academic partnerships. Nat. Chem. Biol. 2(12), 649-653 (2006).
111. Tralau-Stewart CJ. Wyatt CA, Kleyn DE et al. Drug discovery: new models for industry-academic partnerships. Drug Discov. Today 14(1-2), 95-101 (2009).
112. Ohlmeyer M, Zhou MM. Integration of small-molecule discovery in academic biomedical research. Mt. Sinai J. Med. 77(4), 350-357 (2010).
113. Freeman MW, Dervan AP. The path from bench to bedside: considerations before starting the journey. J. Investig. Med. 25 (2011).
114. Vallance P, Williams P, Dollery C. The future is much closer collaboration between the pharmaceutical industry and academic medical centers. Clin. Pharmacol. Ther. 87(5), 525-527 (2010).
115. Ivinson AJ, Lane R, May PC et al. Partnership between academia and industry for drug discovery in Alzheimer's disease. Alzheimers Dement. 4(2), 80-88 (2008).
116. Crowley WF, Gusella JF. Changing models of biomedical research. Sci. Transl. Med. 1(1), 1cm1 (2009).
117. Hughes B. Pharma pursues novel models for academic collaboration. Nat. Rev. Drug Discov. 7(8), 631-632 (2008).
118. Boccanfuso AM. Why university-industry partnerships matter. Sci. Transl. Med. 2(51), 51cm25 (2010).
119. Joly Y. Open biotechnology: licenses needed. Nat. Biotechnol. 28(5), 417-419 (2010).
120. Talaga P. The future of pharmaceutical R&D: somewhere between open and reverse innovation? Future Med. Chem. 2(9), 1399-1403 (2010).